About: Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management
Creator	Osborne, Christina Ang, Jocelyn Campbell, M Katz, Sophie Jaggi, Preeti Lighter, Jennifer Nakra, Natasha Oster, Matthew Choueiter, Nadine Abuali, Mayssa Gertz, Shira Mongkolrattanothai, Kanokporn Olivero, Rosemary Ballan, Wassim Basu, Sanmit Chikkabyrappa, Sathish Clouser, Katherine Corwin, Daniel Dove, Matthew Edwards, Amy Ghassemzadeh, Rod Jarrah, Rima Kelleman, Michael Knutson, Stacie Kuebler, Joseph Mikesell, Christine Morton, Ted Panesar Aa, Laurie Parsons, Sarah Patel Bb, Rupal Schuette, Jennifer Thacker Dd, Deepika Tremoulet Ee, Adriana Vidwan Ff, Navjyot
Source	MedRxiv
abstract	Background: In the absence of evidence-based therapies for Multisystem Inflammatory Syndrome in Children (MIS-C), we aimed to describe the similarities and differences in the evaluation and treatment of MIS-C at hospitals in the United States. Methods: We conducted a cross-sectional survey from June 16 to July 16, 2020 of U.S. pediatric hospitals regarding protocols for patients with MIS-C. Elements included hospital characteristics, clinical definition of MIS-C, evaluation, treatment, and follow-up. We summarized key findings and compared results from centers that had treated >5 patients vs. those that had treated <5 patients. Results: Forty centers of varying size and experience with MIS-C participated. About half (21/40) of centers required only 1 day of fever for MIS-C to be considered. In the evaluation of patients, there was often a tiered approach. Intravenous immunoglobulin was the most widely used medication to treat MIS-C (98% of centers). Corticosteroids were listed in 93% of protocols for primarily the moderate or severe cases. Aspirin was commonly used including for mild cases, whereas heparin or low molecular weight heparin were used primarily in severe cases. In severe cases, anakinra and vasopressors were frequently recommended. Nearly all centers (39/40) recommended follow up with cardiology. There were similar findings between centers that had treated >5 patients vs. those that had treated <5 patients. A supplement containing hospital protocols is provided. Conclusion: There are many similarities yet some key differences between hospital protocols for MIS-C. These findings can help healthcare providers learn from others regarding options for managing MIS-C patients.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.1101/2020.07.29.20164459
has license	medrxiv
sha1sum (hex)	78a955118fba53c0fbcac93e0531c3da24bc900b
schema:url	https://doi.org/10.1101/2020.07.29.20164459
resource representing a document's title	Multisystem Inflammatory Syndrome in Children: Survey of Early Hospital Evaluation and Management
resource representing a document's body	covid:78a955118fba53c0fbcac93e0531c3da24bc900b#body_text
is schema:about of	named entity 'chain reaction' named entity 'Data' named entity 'Survey' named entity 'Evaluation' named entity 'Syndrome' named entity 'Paediatric' named entity 'SARS-CoV-2' named entity 'Kawasaki Disease' named entity 'PCR' named entity 'Inflammatory' named entity 'intravenous immunoglobulin' named entity 'IVIG' named entity 'Inflammatory' named entity 'MIS' named entity 'Multisystem' named entity 'MIS' named entity 'MIS-C' named entity 'hyperinflammation' named entity 'organ' named entity 'Fisher's exact test' named entity 'aspirin' named entity 'MIS' named entity 'systolic' named entity 'American Academy of Pediatrics' named entity 'MIS-C' named entity 'electrocardiogram' named entity 'MIS' named entity 'cardiology' named entity 'signs and symptoms' named entity 'infection' named entity 'MIS-C' named entity 'MIS-C' named entity 'warfarin' named entity 'MIS' named entity 'aspirin' named entity 'left ventricular' named entity 'infectious disease' named entity 'MIS-C' named entity 'fever' named entity 'evidence-based guidelines' named entity 'blood culture' named entity 'basic metabolic panel' named entity 'data integration' named entity 'MIS-C' named entity 'febrile' named entity 'erythrocyte sedimentation rate' named entity 'follow-up' named entity 'cross-sectional survey' named entity 'MIS-C' named entity 'MIS-C' named entity 'Electronic Data Capture' named entity 'vasopressors'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software